Curis Showcases Promising Emavusertib Data at Upcoming Neuro-Oncology Conference
- Curis will present significant findings on emavusertib, an IRAK4 inhibitor, at the 30th SNO Annual Meeting in November 2025.
- Presentations will explore emavusertib's potential in CNS lymphomas, highlighting its efficacy in combination with BTK inhibitors.
- Curis emphasizes precision medicine and collaboration, aiming to improve outcomes for patients with challenging CNS malignancies.
Curis Advances Neuro-Oncology Research with Promising Emavusertib Data Presentation
Curis, Inc., a biotechnology firm focused on innovative cancer therapies, prepares to showcase significant research findings on emavusertib, an orally available IRAK4 inhibitor, at the upcoming 30th Annual Meeting of the Society for Neuro-Oncology (SNO) from November 19-23, 2025. This meeting serves as a pivotal platform for Curis to present both clinical and preclinical data highlighting the potential of emavusertib in treating complex central nervous system (CNS) lymphomas. The company’s commitment to advancing treatment options is evident as it gears up for a series of presentations that could reshape therapeutic approaches for relapsed or refractory CNS lymphoma patients.
Among the presentations, Dr. Christian Grommes from Memorial Sloan Kettering Cancer Center will explore the genetic mutation profile and CNS pharmacokinetics of patients responding to emavusertib in combination with Bruton’s tyrosine kinase inhibitors (BTKis). This analysis, scheduled for November 21, 2025, promises to provide critical insights into the underlying biology of CNS lymphomas and the mechanisms of action of these treatment combinations. Additionally, Dr. Lakshmi Nayak from Dana-Farber Cancer Institute will present preliminary safety and efficacy data for the emavusertib and Ibrutinib combination, further validating the therapeutic potential of emavusertib in challenging patient populations.
The presentation lineup continues to emphasize Curis's focus on precision medicine, with Dr. Grommes returning on November 22 to delve deeper into genetic mutation analysis. Cecilia A. Merrigan from Mayo Clinic will also present findings on the efficacy signals observed in Secondary CNS Lymphoma patients treated with the emavusertib-Ibrutinib combination. Concluding the series, Christina von Roemeling from the University of Florida will address innovative strategies to enhance immunotherapy for melanoma brain metastases by targeting Myddosome signaling. These presentations not only underscore the collaborative effort of leading institutions but also highlight Curis’s strategic direction in developing combination therapies that address unmet needs in neuro-oncology.
Curis’s participation in the SNO meeting underscores its dedication to engaging with the neuro-oncology community and disseminating crucial research findings. This engagement offers a unique opportunity to foster collaborations and share insights that may lead to improved outcomes for patients grappling with difficult-to-treat CNS malignancies. As the company continues to push the boundaries of cancer treatment, the SNO meeting serves as a critical juncture for highlighting emavusertib’s potential and advancing the discourse on innovative cancer therapies.
